[ACAD] ACADIA Pharmaceuticals Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 29.75 Change: 2.08 (7.52%)
Ext. hours: 29.65 Change: -0.1 (-0.34%)

chart ACAD

Refresh chart

Strongest Trends Summary For ACAD

ACAD is in the long-term up 880% in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.61 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -85.71% Sales Growth - Q/Q-91.67% P/E-10.38
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-38.09% ROE-40.35% ROI
Current Ratio18.01 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-123217% Net Profit Margin-122364% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.44 M Cash From Investing Activities38.47 M Cash From Operating Activities-25.35 M Gross Profit
Net Profit-40.38 M Operating Profit-40.55 M Total Assets301.96 M Total Current Assets299.9 M
Total Current Liabilities16.65 M Total Debt Total Liabilities16.87 M Total Revenue
Technical Data
High 52 week39.14 Low 52 week15.12 Last close17.87 Last change1.53%
RSI52.92 Average true range0.66 Beta1.75 Volume3.38 M
Simple moving average 20 days0.08% Simple moving average 50 days-2.47% Simple moving average 200 days-35.73%
Performance Data
Performance Week2.47% Performance Month-2.14% Performance Quart-30.98% Performance Half-40.61%
Performance Year-34.78% Performance Year-to-date-40.65% Volatility daily1.95% Volatility weekly4.36%
Volatility monthly8.94% Volatility yearly30.98% Relative Volume1230.89% Average Volume2.95 M
New High New Low


2019-11-18 10:17:03 | Medtronic MDT to Report Q2 Earnings: What's in Store?

2019-11-12 08:18:01 | The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

2019-11-11 16:48:26 | IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity

2019-11-11 09:28:02 | 4 Biotech Stocks That Could Keep Beating Wall Street

2019-11-11 09:00:00 | ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease CTAD Meeting on December 4, 2019

2019-11-07 05:13:59 | Have Insiders Been Selling ACADIA Pharmaceuticals Inc. NASDAQ:ACAD Shares?

2019-11-06 10:00:03 | What Makes Acadia Pharmaceuticals ACAD a Strong Momentum Stock: Buy Now?

2019-11-06 09:00:02 | Acadia ACAD Upgraded to Buy: Here's Why

2019-11-04 09:00:00 | ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer

2019-11-03 15:03:24 | Edited Transcript of ACAD earnings conference call or presentation 30-Oct-19 8:30pm GMT

2019-10-30 19:25:11 | Acadia Pharmaceuticals ACAD Reports Q3 Loss, Tops Revenue Estimates

2019-10-30 16:15:00 | ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder

2019-10-30 16:05:00 | ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results

2019-10-29 08:46:12 | Cigna CI to Report Q3 Earnings: What's in the Offing?

2019-10-28 11:22:03 | Teladoc TDOC to Report Q3 Earnings: What's in the Cards?

2019-10-25 12:12:04 | Will Nuplazid Aid Growth for ACADIA ACAD in Q3 Earnings?

2019-10-24 16:58:59 | Hedge Funds Are Betting On ACADIA Pharmaceuticals Inc. ACAD Again

2019-10-23 10:33:02 | Acadia Pharmaceuticals ACAD May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-10-16 09:00:00 | ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019

2019-10-09 11:18:03 | Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

2019-10-08 06:00:00 | Acadia Sees Strong Results in Dementia Treatment

2019-10-07 09:00:00 | ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress

2019-10-03 16:55:00 | ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease CTAD 2019 Meeting

2019-10-02 06:37:50 | We Think ACADIA Pharmaceuticals NASDAQ:ACAD Can Easily Afford To Drive Business Growth

2019-09-26 09:14:01 | Should First Trust Mid Cap Growth AlphaDEX Fund FNY Be on Your Investing Radar?

2019-09-25 16:05:00 | ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

2019-09-24 16:05:00 | ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder

2019-09-23 09:00:00 | ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders

2019-09-20 16:05:00 | ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2019-09-20 13:10:14 | Gilead, AbbVie Are Innovative, but May Be Underappreciated

2019-09-19 09:00:00 | ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings

2019-09-17 23:00:00 | ACADIA Pharmaceuticals Prices Public Offering of Common Stock

2019-09-17 16:02:00 | ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

2019-09-17 15:25:42 | 5 Top Stock Trades for Wednesday: BA, ACB, PINS

2019-09-11 10:23:43 | 3 Hot Biotechs with High Upside Potential

2019-09-10 13:20:40 | 'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis

2019-09-10 11:41:03 | ACADIA Surges on Early Success of Nuplazid Dementia Study

2019-09-10 10:59:02 | Will ACADIA Continue to Surge Higher?

2019-09-10 08:39:00 | Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now?

2019-09-10 07:36:12 | The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

2019-09-09 17:38:00 | Why Acadia Pharmaceuticals Stock Skyrocketed Today

2019-09-09 16:55:24 | ACADIA Pharmaceuticals Help Lift Biotech ETFs

2019-09-09 16:26:30 | Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High

2019-09-09 16:13:00 | What Happened in the Stock Market Today

2019-09-09 14:33:33 | Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related Psychosis

2019-09-09 12:17:30 | A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019

2019-09-09 10:26:18 | Options Hot as ACADIA Pharmaceuticals Stock Soars

2019-09-09 09:05:01 | ACADIA Enters Oversold Territory

2019-09-09 07:31:00 | [video]Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment

2019-09-09 07:26:00 | Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint